文献速递慢性肾脏病肾小球疾病

达格列净在4期慢性肾脏病中的效果

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2021-07-16

达格列净使主要复合终点风险降低27%(95%CI -2至47%),eGFR斜率下降更缓(组间差异P=0.005),安全性与安慰剂相似。

要点

  • 4期CKD伴白蛋白尿患者中,达格列净主要复合终点风险降低27%(95%CI -2至47%)。
  • 达格列净组eGFR年下降2.15 ml/min/1.73 m2,安慰剂组3.38 ml/min/1.73 m2(P=0.005)。
  • 严重不良事件和关注的不良事件发生率与安慰剂相似。

核心结论

  • 在4期CKD伴白蛋白尿患者中,达格列净的疗效与DAPA-CKD总体试验一致,未发现风险增加。

主要发现

  • 达格列净组主要复合终点风险降低27%(95%CI -2至47%),肾脏复合终点降低29%(95%CI -2至51%),心血管复合终点降低17%(95%CI -53至55%),全因死亡降低32%(95%CI -21至61%)。
  • 与2/3期CKD相比,4期CKD的交互作用P值分别为0.22、0.13、0.63和0.95。
  • eGFR斜率在达格列净组和安慰剂组分别为每年下降2.15和3.38 ml/min/1.73 m2(P=0.005)。
  • 达格列净组与安慰剂组的严重不良事件和关注的不良事件发生率相似。

临床怎么用

  • 对于4期CKD伴白蛋白尿的患者,可考虑使用达格列净以降低肾脏和心血管事件风险,但需注意主要终点置信区间下限接近零。

局限性

  • 该分析为预设亚组分析,样本量有限,主要终点置信区间较宽且下限接近零。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes. METHODS: Adults with eGFR of 25-75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio of 200-5000 mg/g had been randomized to receive dapagliflozin 10 mg/d or placebo. Here, we conducted a prespecified analysis of dapagliflozin's effects in patients with stage 4 CKD (eGFR,30 ml/min per 1.73 m2) at baseline. The primary end point was a composite of time to ≥50% sustained decline in eGFR, ESKD, or kidney or cardiovascular death. Secondary end points were a kidney composite (same as the primary end point but without cardiovascular death), a composite of cardiovascular death or heart failure hospitalization, and all-cause death. RESULTS: A total of 293 participants with stage 4 CKD received dapagliflozin and 331 received placebo. Patients with stage 4 CKD randomized to dapagliflozin experienced a 27% (95% confidence interval [95% CI]: -2 to 47%) reduction in the primary composite endpoint, and 29% (-2 to 51%), 17% (-53 to 55%), and 32% (-21 to 61%) reductions in the kidney, cardiovascular and mortality endpoints, respectively, relative to placebo. Interaction P-values were 0.22, 0.13, 0.63, and 0.95, respectively, comparing CKD stages 4 versus 2/3. The eGFR slope declined by 2.15 and 3.38 ml/min per 1.73 m2 per year in the dapagliflozin and placebo groups, respectively (P=0.005). Patients treated with dapagliflozin or placebo had similar rates of serious adverse events and adverse events of interest. CONCLUSIONS: Among patients with stage 4 CKD and albuminuria, the effects of dapagliflozin were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Chertow GM, Vart P, Jongs N, et al. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021. PMID: 34272327. doi:10.1681/ASN.2021020167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。